Healthcare Industry News: telemedicine
News Release - June 14, 2006
CHF Solutions Names David B. Springer President and Chief Operating OfficerExecutive to Focus on Building Sales for Innovative Heart Failure Treatment
BROOKLYN PARK, Minn.--(HSMN NewsFeed)--June 14, 2006--CHF Solutions, Inc., has named David B. Springer president and chief operating officer, effective immediately. Springer will be responsible for the global leadership of CHF Solutions' sales, marketing, R&D and operations staff. He plans to leverage the company's landmark clinical trial results to expand sales and marketing efforts for the Aquadex FlexFlow(TM), the company's innovative system used to treat fluid overload in heart failure patients.
"I am very excited to have Dave join our executive leadership team," said John Erb, chief executive officer of CHF Solutions. "Dave brings great strengths to CHF Solutions. We will benefit immensely from his experience commercializing new technologies, his proven record of success and his passion."
Most recently, Springer served as senior vice president of the U.S. Division of St. Jude Medical, where he drove the domestic strategy and operational plan, as well as had primary brand management accountability. From 2000 to 2002, Springer was the chief operating officer at AndyDevice (acquired by Hiddenmind Technology), a turnaround where he successfully realigned the business focus toward ambitious growth. Previously, he held the positions of executive vice president of business development and senior vice president of sales at WebMD, where he played a critical role on the founding management team, transforming and building a start-up medical device and telemedicine company into the nation's leading Internet healthcare business. Earlier, he held various leadership, sales and marketing roles at Intermedics, Kimberly Clark Healthcare and Procter & Gamble.
"On the heels of the very positive UNLOAD study results announced at the American College of Cardiology conference, this company has all the right pieces in place for great commercial success," said Springer. "We believe that the significant clinical benefits for patients with fluid overload shown by UNLOAD can translate into economic benefits for hospitals and health plans."
Springer graduated from Purdue University in 1986 with a bachelor's degree in industrial management and a minor in industrial engineering.
About the UNLOAD study
UNLOAD is a randomized, multicenter study of 200 patients involving 28 hospitals and medical centers across the U.S. that details the immediate and long-term benefits for heart failure patients receiving Aquapheresis(TM) therapy to treat fluid overload. It is the first randomized clinical study of its type to compare the safety and efficacy of treatment with the Aquadex FlexFlow system, a non-drug-based option, with standard intravenous diuretic drug therapy to treat fluid overload in heart failure patients. Its landmark results were first presented at the 2006 American College of Cardiology conference in March. For more information about the UNLOAD study, go to http://www.chfsolutions.com/unload_lbct.html.
About Fluid Overload and Heart Failure
Fluid overload can be caused by many things, including problems with the heart, kidneys, lungs or any combination of these vital organs. The leading cause of fluid overload is congestive heart failure (CHF), sometimes referred to as heart failure (HF).
Heart failure is a condition that affects approximately 5 million Americans and is responsible for one million hospitalizations annually. More than 500,000 new cases of heart failure are diagnosed each year. The estimated economic burden of heart failure care exceeds $28 billion annually in the United States. Due to prolonged hospitalizations and high readmission rates, many hospitals often lose more than $1,000 for each heart failure patient admitted.
About Aquapheresis, the Aquadex FlexFlow and CHF Solutions
CHF Solutions' Aquapheresis therapy with the Aquadex FlexFlow system allows physicians to remove the excess salt and water in patients with fluid overload where, when and how they want. Inpatient or outpatient, peripheral or central venous access, its low blood flow, low extracorporeal blood volume, and precise removal rates enable dependable fluid removal.
CHF Solutions, based in Brooklyn Park, Minn., is a privately held manufacturer of medical devices for cardiac care. The company's mission is to provide medical practitioners with innovative and practical solutions that enable the treatment of patients with unmet clinical needs. For more information, go to www.chfsolutions.com.
Source: CHF Solutions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.